CN116672355A - Application of carboxymethyl xylan zinc complex in health care medicine or food - Google Patents
Application of carboxymethyl xylan zinc complex in health care medicine or food Download PDFInfo
- Publication number
- CN116672355A CN116672355A CN202310536775.XA CN202310536775A CN116672355A CN 116672355 A CN116672355 A CN 116672355A CN 202310536775 A CN202310536775 A CN 202310536775A CN 116672355 A CN116672355 A CN 116672355A
- Authority
- CN
- China
- Prior art keywords
- xylan
- carboxymethyl
- zinc complex
- zinc
- carboxymethyl xylan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001221 xylan Polymers 0.000 title claims abstract description 67
- 150000004823 xylans Chemical class 0.000 title claims abstract description 52
- 239000011701 zinc Substances 0.000 title claims abstract description 45
- 229910052725 zinc Inorganic materials 0.000 title claims abstract description 43
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 title claims abstract description 38
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 title claims abstract description 29
- 239000003814 drug Substances 0.000 title claims abstract description 12
- 235000013305 food Nutrition 0.000 title claims abstract description 9
- 230000036541 health Effects 0.000 title claims abstract description 9
- 230000007413 intestinal health Effects 0.000 claims abstract description 6
- 229940079593 drug Drugs 0.000 claims abstract description 5
- 235000013402 health food Nutrition 0.000 claims abstract description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 45
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 28
- 230000000694 effects Effects 0.000 claims description 11
- 239000012153 distilled water Substances 0.000 claims description 10
- 230000001105 regulatory effect Effects 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 7
- 238000004108 freeze drying Methods 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 239000007902 hard capsule Substances 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000007901 soft capsule Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- -1 carboxymethyl xylan Chemical class 0.000 abstract description 18
- 241000699670 Mus sp. Species 0.000 abstract description 10
- 229940106681 chloroacetic acid Drugs 0.000 abstract description 8
- 238000006243 chemical reaction Methods 0.000 abstract description 7
- 210000003736 gastrointestinal content Anatomy 0.000 abstract description 7
- 238000010668 complexation reaction Methods 0.000 abstract description 6
- 238000000034 method Methods 0.000 abstract description 5
- 238000011160 research Methods 0.000 abstract description 4
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 239000000376 reactant Substances 0.000 abstract description 3
- 230000035484 reaction time Effects 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 abstract description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 15
- 239000000243 solution Substances 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- 230000037406 food intake Effects 0.000 description 8
- 235000012631 food intake Nutrition 0.000 description 8
- 210000001072 colon Anatomy 0.000 description 6
- 230000037396 body weight Effects 0.000 description 4
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 150000004666 short chain fatty acids Chemical class 0.000 description 4
- 229920002488 Hemicellulose Polymers 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 210000004534 cecum Anatomy 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 235000021391 short chain fatty acids Nutrition 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000000536 complexating effect Effects 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000002715 modification method Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 244000166124 Eucalyptus globulus Species 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010048259 Zinc deficiency Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 238000006277 sulfonation reaction Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0057—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Xylans, i.e. xylosaccharide, e.g. arabinoxylan, arabinofuronan, pentosans; (beta-1,3)(beta-1,4)-D-Xylans, e.g. rhodymenans; Hemicellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
- A23L33/165—Complexes or chelates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Polymers & Plastics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Food Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Materials Engineering (AREA)
Abstract
The invention relates to an application of carboxymethyl xylan zinc complex in health care drugs or foods, belonging to the fields of health care foods and drug research. And adopting a NaOH-chloroacetic acid method to carry out carboxymethyl modified xylan, observing the influences of three factors of reactant mass ratio, reaction temperature and reaction time by a single factor to obtain the optimal condition of zinc complexation, and carrying out zinc complexation reaction on carboxymethyl xylan under the condition to obtain carboxymethyl xylan zinc complex. The invention uses the artificially synthesized carboxymethyl xylan zinc complex for the test of the internal intestinal contents of mice, and the vital sign analysis result reflects the beneficial effect of the carboxymethyl xylan zinc complex on the intestinal health, thereby providing a reference basis for the application of the carboxymethyl xylan zinc complex in the fields of health food and medicine research.
Description
Technical Field
The invention relates to an application of carboxymethyl xylan zinc complex in health care drugs or foods, belonging to the field of medicine health care products and food research.
Background
Xylan is the most abundant hemicellulose in nature, and its content and structure vary from species to species. The xylan backbone has a number of hydroxyl groups which can be chemically modified to attach other groups to modify the nature and bioactivity of the xylan. Thus, xylan can be modified to investigate its biological activity.
The modification method of xylan mainly comprises carboxymethylation, acetylation and sulfation, and can obtain xylan derivatives through methylation, sulfonation, phosphorylation and other methods. Wherein carboxymethylation is a modification method for obtaining water-soluble anionic xylan derivatives, and can also improve the water solubility of xylan. Chen Ting and the like extract hemicellulose (the main component is xylan) from eucalyptus waste liquid, and the hemicellulose is subjected to carboxymethylation modification, wherein the highest substitution degree of carboxymethyl is 1.47, and the experimental determination shows that the derivative has better effects on oxidation resistance, hygroscopicity, moisture retention and bacteriostasis than before modification.
Short Chain Fatty Acids (SCFAs) are the primary energy sources for endogenous microbiota and intestinal epithelial cells, associated with intestinal health and certain metabolic functions. The pH drop of the colon and cecal contents is largely dependent on the increase in SCFAs concentration, which has been demonstrated in other studies. The cecum bacterial community has more than 200 different non-starch polysaccharide degrading enzymes, and has stronger capability of degrading xylan, pectin and cellulose. Thus, low pH in the colon, cecum and stool favors the formation of a good intestinal microenvironment.
Zinc is not only one of the microelements necessary for human body, but also the microelements with the second most abundant content in human body. Zinc deficiency is mainly due to insufficient uptake and absorption of zinc, and if zinc is deficient, various diseases or nutritional deficiencies may result. Thus, the present invention chelates the carboxymethyl xylan with zinc to form a complex, and explores its effect on intestinal health and its value.
Disclosure of Invention
The invention aims to provide a preparation method of a carboxymethyl xylan zinc complex, which utilizes an in-vivo intestinal content test of a mouse to determine the effect of the carboxymethyl xylan zinc complex on benefiting intestinal health and provides a reference basis for application of the carboxymethyl xylan zinc complex in the fields of health food and medicine research.
A preparation method of carboxymethyl xylan complex specifically comprises the following steps: and (3) carrying out carboxymethyl modified xylan by using a NaOH-chloroacetic acid method, then observing the influences of three factors of reactant mass ratio, reaction temperature and reaction time by a single factor to obtain the optimal condition of zinc complexation, and carrying out zinc complexation reaction on carboxymethyl xylan under the condition to obtain carboxymethyl xylan zinc complex. NaOH-chloroacetic acid method for modifying xylan: dissolving xylan in an ice water bath 3 h of a mixed water solution of isopropanol and NaOH, dissolving chloroacetic acid in the mixed water solution of isopropanol and NaOH, slowly dripping the chloroacetic acid into the mixed water solution of isopropanol and NaOH, reacting at 65 ℃ for 3 h, cooling, regulating the pH to 6.5 by using hydrochloric acid, dialyzing with running water for 48 h, and freeze-drying to obtain carboxymethyl xylan; single factor experiments were performed: dissolving carboxymethyl xylan in distilled water under stirring, adding appropriate amount of ZnSO 4 ·7H 2 O, regulating the pH to 5.5 by NaOH, reacting for several hours at a certain temperature, dialyzing by running water for 48 and h, concentrating, freeze-drying to obtain carboxymethyl xylan zinc complex, and finally determining the optimal condition of zinc complex; preparing carboxymethyl xylan zinc complex under optimal zinc complexing conditions: adding carboxymethyl xylan into distilled water, stirring at normal temperature for dissolving for 10 min, and adding appropriate amount of ZnSO 4 ·7H 2 Regulating pH to 5.5 with NaOH, reacting at 55deg.C with 3 h, dialyzing with running water with 48 h, concentrating, and freeze dryingTo a carboxymethyl xylan zinc complex.
The invention achieves the aim through the following technical scheme:
(1) Preparing carboxymethyl xylan by adopting a NaOH-chloroacetic acid method: after dissolving xylan in a mixed water solution of isopropanol and 20% NaOH, carrying out ice water bath 3-h, dissolving chloroacetic acid in a mixed water solution of isopropanol and 20% NaOH, uniformly mixing, slowly dripping into a xylan reaction system, and reacting at 65 ℃ 3-h. After cooling, the pH was adjusted to 6.5 with hydrochloric acid, and the mixture was dialyzed against running water, 48. 48 h, and lyophilized to give Carboxymethyl Xylan (CXY).
(2) And (3) carrying out a single factor experiment to respectively examine the influence of the reactant mass ratio, the reaction temperature and the reaction time on the complexation reaction: dissolving carboxymethyl xylan in distilled water under stirring, adding ZnSO with different mass ratios (Zn: CXY 0.1, 0.2, 0.3, 0.4, 0.5) 4 ·7H 2 O, pH is regulated to 5.5 by NaOH solution, the reaction is carried out for several hours (1, 2, 3, 4, 5 and h) at different temperatures (45, 50, 55, 60 and 65 ℃), 48 h is dialyzed by running water, concentration and freeze drying are carried out, and the optimal condition of zinc complexation is determined.
(3) Preparing carboxymethyl xylan zinc complex under optimal zinc complexing conditions: dissolving carboxymethyl xylan in distilled water, stirring at normal temperature for 10 min, adding ZnSO with Zn to CXY mass ratio of 0.3 4 ·7H 2 O, pH is regulated to 5.5 by NaOH, reaction is carried out at 55 ℃ for 3 h, running water is dialyzed for 48 h, concentration and freeze drying are carried out, and the carboxymethyl xylan zinc complex is obtained.
Drawings
FIG. 1 is a graph showing the effect of the zinc carboxymethyl xylan complex described in examples 1-3 on mouse body weight
FIG. 2 is a graph showing the effect of the zinc carboxymethyl xylan complex described in examples 1-3 on the feeding rate of mice
FIG. 3 is a graph showing the effect of the zinc carboxymethyl xylan complex described in examples 1-3 on the pH of the intestinal contents of mice
Detailed Description
In order to facilitate understanding of the application of the zinc carboxymethyl xylan complex in health care drugs or foods, the following examples of the present invention are given to further illustrate the technical solution of the present invention, but the scope of the present invention is not limited thereby.
Example 1:
50. 50 mL isopropyl alcohol and 25 mL of 20% NaOH aqueous solution were added to 3.0 g xylan, ice water bath 3 h. Then adding 50 mL isopropanol and 25 mL of 20% NaOH aqueous solution into 15.0 g chloroacetic acid, uniformly mixing, slowly dripping into the xylan reaction system, and reacting at 65 ℃ for 3 h. After cooling, pH was adjusted to 6.5 with 1. 1M hydrochloric acid, dialyzed against running water, 48. 48 h, and lyophilized to give carboxymethyl xylan.
The prepared carboxymethylated xylan is weighed 1.0 g and dissolved in 450 mL distilled water, stirred and dissolved for 10 min at normal temperature, and 0.88 g ZnSO is added 4 ·7H 2 O (dissolved in 20 ml of 0.1 mol/L HCl), pH was adjusted to 5.5 with 1 mol/L NaOH solution, and the mixture was reacted at 50℃for 2. 2 h, dialyzed with running water for 48. 48 h, concentrated, and lyophilized to give a carboxymethyl xylan zinc complex (hereinafter referred to as CXY-Zn-1).
Example 2:
weighing 1.0. 1.0 g carboxymethylated xylan, dissolving in 450 mL distilled water, stirring at normal temperature for 10 min, adding 1.32 g ZnSO 4 ·7H 2 O (dissolved in 20 ml of 0.1 mol/L HCl), pH was adjusted to 5.5 with 1 mol/L NaOH solution, and the mixture was reacted at 55℃for 3. 3 h, dialyzed with running water for 48. 48 h, concentrated, and lyophilized to give a carboxymethyl xylan zinc complex (hereinafter referred to as CXY-Zn-2).
Example 3:
weighing 1.0. 1.0 g carboxymethylated xylan, dissolving in 450 mL distilled water, stirring at normal temperature for 10 min, and adding 1.76 g ZnSO 4 ·7H 2 O (dissolved in 20 ml of 0.1 mol/L HCl), pH was adjusted to 5.5 with 1 mol/L NaOH solution, and the mixture was reacted at 60℃with 4. 4 h, dialyzed with running water, 48. 48 h, concentrated, and lyophilized to give a carboxymethyl xylan zinc complex (hereinafter referred to as CXY-Zn-3).
Example 4:
the effect of CXY-Zn-1, CXY-Zn-2, CXY-Zn-3 and Xylan (XY) on mouse body weight, food intake and intestinal content pH was studied. The mice were randomly divided into 5 groups, and a blank group and an experimental group were set for comparison, which were a normal group (N), a CXY-Zn-1 group, a CXY-Zn-2 group, a CXY-Zn-3 group and an XY group, respectively. Mice were first conditioned for one week at an experimental ambient temperature of 24±2 ℃ and humidity of 40% -60% with free water and food intake during the experiment, and the gastric lavage dose of the mice was 0.4 g/kg/d. Samples were prepared using sterile distilled water prior to each lavage. The normal group was perfused with the corresponding amount of sterile distilled water at the same time of day for 14 days. At the end of the experiment, intestinal contents were collected after removal of the colon and cecum.
(1) Body weight and food intake
The effect of the carboxymethyl xylan zinc complex prepared in the examples 1-3 on the weight and the food intake of mice is studied, and the results are shown in figures 1 and 2, the growth and development states of the mice are good, the weights of all treatment groups are not obviously different, the weight change of a normal group is stable, and the weights of the other treatment groups fluctuate up and down within a certain range; the food intake of the normal group is gentle, and the food intake of each group is not obviously different, and the food intake of the normal group is approximately in a normal distribution state with the normal group as the center. It was demonstrated that CXY-Zn-1, CXY-Zn-2, CXY-Zn-3 and xylan did not have a significant adverse effect on the body weight and the food intake of mice.
(2) Intestinal content pH
The effect of the zinc carboxymethyl xylan complex prepared in examples 1-3 on the pH of the intestinal contents of mice was studied, and as shown in FIG. 3, the pH of the colon contents of the normal group was 7.04, the pH of the colon contents of the CXY-Zn-1, CXY-Zn-2 and CXY-Zn-3 groups was 6.90, 6.59 and 6.66, respectively, each lower than that of the XY group (6.98), and the pH of the colon contents of the CXY-Zn-2 group was reduced to a greater extent. The cecal content pH of the normal group was 7.73, whereas the CXY-Zn-2 group cecal content pH was significantly down-regulated at 5.33, lower than that of the normal group (P < 0.05), and the CXY-Zn-1 and CXY-Zn-3 groups cecal content pH were both lower than that of the normal group, but none of the CXY-Zn-2 groups was significantly. The results show that the carboxymethyl xylan zinc complex prepared under the optimal conditions in the example 2 is most beneficial to reducing the pH value of the intestinal tract, and the carboxymethyl xylan zinc complex can promote the production of short-chain fatty acid to a certain extent, reduce the pH value of the intestinal tract environment and is beneficial to the health of the intestinal tract.
Claims (2)
1. An application of carboxymethyl xylan zinc complex in health care medicine or food, which is characterized in that:
dissolving carboxymethylated xylan 1.0. 1.0 g in 450 mL distilled water, stirring at room temperature for 10 min, and adding ZnSO 1.32 g 4 ·7H 2 O (dissolved in 20 ml of 0.1 mol/L HCl), regulating pH to 5.5 with 1 mol/L NaOH solution, reacting at 55deg.C for 3 h, dialyzing with running water for 48 h, concentrating, and freeze drying to obtain carboxymethyl xylan zinc complex;
the carboxymethyl xylan zinc complex has the effect of benefiting intestinal health and is applied to the preparation of medicines or health-care foods for assisting in maintaining intestinal health.
2. The use according to claim 1, characterized in that: the dosage forms of the medicine or the health food are tablets, granules, hard capsules, soft capsules, oral liquid, powder, mixture, pills, dripping pills, pharmaceutically acceptable carriers and auxiliary materials.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310536775.XA CN116672355A (en) | 2023-05-12 | 2023-05-12 | Application of carboxymethyl xylan zinc complex in health care medicine or food |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310536775.XA CN116672355A (en) | 2023-05-12 | 2023-05-12 | Application of carboxymethyl xylan zinc complex in health care medicine or food |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116672355A true CN116672355A (en) | 2023-09-01 |
Family
ID=87788150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310536775.XA Pending CN116672355A (en) | 2023-05-12 | 2023-05-12 | Application of carboxymethyl xylan zinc complex in health care medicine or food |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116672355A (en) |
-
2023
- 2023-05-12 CN CN202310536775.XA patent/CN116672355A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Vince et al. | The effect of lactulose, pectin, arabinogalactan and cellulose on the production of organic acids and metabolism of ammonia by intestinal bacteria in a faecal incubation system | |
| CN111087484B (en) | Bonded selenium polysaccharide and preparation method and application thereof | |
| US11345761B2 (en) | Esterified selenium polysaccharide and preparation method and use therefor | |
| CN101947234A (en) | Preparation method for preparation containing glucosamine and application thereof | |
| TWI291351B (en) | Pharmaceutical composition for lowering blood-sugar | |
| EP1723855B1 (en) | Hydrogels containing gamma-polyglutamic acid (gamma-PGA, H Form) and gamma-polyglutamates for use as nutrition supplements in dietary products | |
| CN111528470A (en) | Preparation method of calcium roxburgh rose complex, product and application thereof | |
| EP2635130B1 (en) | Composition of purified soluble mannans for dietary supplements and methods of use thereof | |
| Han et al. | In vitro fermentation potential of the residue of Korean red ginseng root in a mixed culture of swine faecal bacteria | |
| KR20210012979A (en) | Levan-protein nanocomposite and uses thereof | |
| CN116672355A (en) | Application of carboxymethyl xylan zinc complex in health care medicine or food | |
| CN104582716A (en) | Growth enhancement of infants | |
| EP4368697A1 (en) | High immune yeast cell wall, and preparation method therefor and use thereof | |
| CN101912407A (en) | Weight-reducing and lipid-lowering composition | |
| CN111280453B (en) | Preparation method of antrodia water-insoluble dietary fiber | |
| CN112300299A (en) | Preparation method and application of zinc and calcium polysaccharide complex | |
| KR20210115240A (en) | A method and composition of increasing absorption of minerals using PDRN and N-Acetylglucosamin as active ingredients | |
| CN106692985B (en) | Chrysophanol glucan clathrate and application thereof | |
| DK2865278T3 (en) | Binder fat obtained from biomass, derived from beer production | |
| CN116874643B (en) | Xylan calcium complex and application thereof in antioxidant products | |
| CN110787143A (en) | Metformin hydrochloride tablet and application thereof | |
| CN114403450B (en) | Application of auricularia auricula polysaccharide additive in inhibiting generation of metabolic odor of organism | |
| CN117224690B (en) | Gamma-polyglutamic acid mixture, composition and preparation method as auxiliary agent | |
| CN115487288B (en) | Almond peptide oral liquid and preparation method thereof | |
| CN114522195B (en) | Chinese chestnut almond glycoprotein-coated Chinese chestnut peel pigment nano intestinal probiotics promoter and preparation and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |